NCT05965856

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors

A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B003 Monotherapy and BL-B01D1+SI-B003 Combination Therapy (BL-B01D1+SI-B003) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 52 (estimated)
• Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This phase II study is designed to explore the efficacy and safety of SI-B003 monotherapy and BL-B01D1+SI-B003 combination therapy in patients with locally advanced or metastatic urothelial carcinoma and other solid tumors.

Conditions

• Urothelial Carcinoma
• Solid Tumor

Interventions

Type	Name	Description
DRUG	BL-B01D1	Administration by intravenous infusion
DRUG	SI-B003	Administration by intravenous infusion

Timeline

• Start date: 2023-12-11
• Primary completion: 2026-12-01
• Completion: 2027-12-01
• First posted: 2023-07-28
• Last updated: 2025-09-26

Locations

1 site across 1 country: China